Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival

Gaelle Mueller-Greven, Cleveland Clinic
Cathleen R. Carlin, Case Western Reserve University
Monica E. Burgett, Cleveland Clinic
Manmeet S. Ahluwalia, Cleveland Clinic
Adam Lauko, Cleveland Clinic
Amy S. Nowacki, Cleveland Clinic
Cameron J. Herting, Emory University
Maha A. Qadan, Cleveland Clinic
Markus Bredel, University of Alabama Birmingham
Steven A. Toms, Geisinger Medical Center

Only first 10 authors above; see publication for full author list.

Journal Title: Clinical Cancer Research
Volume: Volume 23, Number 22
Publisher: American Association for Cancer Research | 2017-11-15, Pages 7059-7071
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1158/1078-0432.CCR-17-0249
Permanent URL: https://pid.emory.edu/ark:/25593/tk6d8

Final published version: http://dx.doi.org/10.1158/1078-0432.CCR-17-0249

Copyright information:
©2017 AACR.

Accessed September 12, 2019 6:56 PM EDT
Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival

Gaëlle Müller-Greven¹,⁵, Cathleen R. Carlin⁶, Monica E. Burgett¹,⁵, Manmeet S. Ahluwalia⁴, Adam Lauko¹, Amy S. Nowacki², Cameron J. Herting⁷, Maha A. Qadan¹,⁵, Markus Bredel⁸, Steven A. Toms⁹, Justin D. Lathia³,⁴, Dolores Hambardzumyan⁷, Jann N. Sarkaria¹⁰, Petra Hamerlik¹¹, and Candece L. Gladson¹,⁴

¹Department of Cancer Biology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195
²Department of Quantitative Health Sciences, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195
³Department of Cell and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195
⁴Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195
⁵School of Biomedical Sciences, Kent State University, Kent, OH
⁶Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland OH
⁷Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
⁸Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL
⁹Department of Neurosurgery, Geisinger Medical Center, Geisinger, PA
¹⁰Department of Radiation Oncology, Mayo Clinic, Rochester, MN
¹¹Brain Tumor Biology, Danish Cancer Society Research Center, Copenhagen, Denmark

Abstract

Purpose—Bevacizumab, a humanized monoclonal antibody to VEGF, is used routinely in the treatment of patients with recurrent glioblastoma (GBM). However, very little is known regarding the effects of bevacizumab on the cells in the perivascular space in tumors.

Experimental Design—Established orthotopic xenograft and syngeneic models of GBM were used to determine entry of monoclonal anti-VEGF-A into, and uptake by cells in, the perivascular space. Based on the results, we examined CD133⁺ cells derived from GBM tumors in vitro. Bevacizumab internalization, trafficking and effects on cell survival were analyzed using multi-label confocal microscopy, immunoblotting and cytotoxicity assays in the presence/absence of inhibitors.

Corresponding Author: Dr. Candece L. Gladson, Department of Cancer Biology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; gladsoc@ccf.org.
**Results**—In the GBM mouse models, administered anti-mouse-VEGF-A entered the perivascular tumor niche and was internalized by Sox2+/CD44+-tumor cells. In the perivascular tumor cells, bevacizumab was detected in the recycling compartment or the lysosomes, and increased autophagy was found. Bevacizumab was internalized rapidly by CD133+/Sox2+-GBM cells in vitro through macropinocytosis with a fraction being trafficked to a recycling compartment, independent of FcRn, and a fraction to lysosomes. Bevacizumab treatment of CD133+ GBM cells depleted VEGF-A and induced autophagy thereby improving cell survival. An inhibitor of lysosomal acidification decreased bevacizumab-induced autophagy and increased cell death. Inhibition of macropinocytosis increased cell death, suggesting macropinocytosis of bevacizumab promotes CD133+ cell survival.

**Conclusions**—We demonstrate that bevacizumab is internalized by Sox2+/CD44+-GBM tumor cells residing in the perivascular tumor niche. Macropinocytosis of bevacizumab and trafficking to the lysosomes promotes CD133+ cell survival, as does the autophagy induced by bevacizumab depletion of VEGF-A.

**Keywords**
Bevacizumab; glioblastoma; macropinocytosis; endocytosis; trafficking; cancer stem cells; endothelial cells; transcytosis

**Introduction**

The microenvironment provided in the perivascular space is emerging as a critical determinant of tumor cell growth and survival (reviewed in (1)). Although humanized IgG monoclonal antibodies (mAbs) are now used in cancer therapy, surprisingly little is known concerning their access to the perivascular space in the brain and the mechanisms by which they affect tumor cells within this microenvironment. Bevacizumab, a humanized bivalent IgG1 mAb, was developed as an anti-angiogenic therapeutic agent. Currently, bevacizumab has FDA approval for use in the treatment of recurrent glioblastoma (GBM) and renal, lung and colon cancer (2). Bevacizumab has been reported to extend the 6-month progression-free survival in patients with recurrent GBM (3,4). Patients with recurrent GBM are now routinely treated with bevacizumab, which induces normalization of some of the tumor vasculature (2) and enhances quality-of-life. In common with other humanized mAbs, the response shows interindividual variability and approximately 20% of patients with recurrent GBM do not show any response to bevacizumab (5). The reasons for this lack of response have not been elucidated and the effects of bevacizumab on the cells in the perivascular niche have not been determined.

It is well established that populations of cells with a cancer stem cell-like phenotype (e.g., expression of the CD133 cell surface marker and of the transcription factor Sox2) are resistant to radiation therapy (6). Thus, alterations in the perivascular microenvironment could provide a niche that promotes and then sustains the development of this population of cells in various cancers, including GBM. Bevacizumab was developed based on its binding of vascular endothelial growth factor-A (VEGF-A) at the site recognized by the VEGF receptor (VEGFR) thereby preventing VEGF-A signaling (reviewed in (2)). As GBM cells with the CD133+ phenotype produce VEGF-A and express VEGFR2, VEGF-A can act in an
autocrine or paracrine manner to promote survival of these cells as well as acting systemically (7,8).

Large molecules can gain access to the perivascular tissue through transcytosis across the endothelial cells (ECs) in the brain, and through alterations in the blood brain barrier (BBB) (9,10). Although it is a reasonable assumption that bevacizumab gains access to the perivascular space in GBM, to our knowledge there are no published reports demonstrating this. One report indicated that human IgG (hIgG) was detectable in tumor lysates of orthotopic GBM xenograft tumors that had been propagated in nude mice administered bevacizumab (11). However, this was based on western blotting of whole tumor lysates and, thus, did not differentiate between the presence of the bevacizumab in the perivascular space and the tumor-associated vessels. Similarly, the possibility that bevacizumab is internalized by GBM tumor cells has not been addressed. Recently, fluorescent-labeled bevacizumab was shown to gain access to invasive breast cancers when injected i.v. prior to mastectomy (12). In ECs, hIgG is thought to be taken up by a pinocytotic process and to bind the embryonic Fc receptor (FcRn), which recycles hIgG and is localized at the early endosome (13,14). FcRn is expressed in brain ECs (13,14), but was found recently either to be undetectable or present at very low levels in a large number of tumor cell lines and that when present it acts as a tumor suppressor by recycling albumin (15). Large molecules also can be internalized through the non-selective process of macropinocytosis. Macropinocytosis is initiated from plasma membrane ruffles that give rise to actin-containing plasma membrane extensions, resulting in large endocytic vacuoles called macropinosomes that ultimately become early endosomes (reviewed in (16,17)). The cargo within early endosomes can be trafficked to a recycling compartment or the lysosome (16,17). Macropinocytosis has been shown to be a mechanism by which Ras-transformed cells and starving cells engulf extracellular proteins and then lysosomally degrade the proteins, thereby promoting their own proliferation and survival (18,19).

Here, we report that bevacizumab and hIgG gain access to the perivascular space in orthotopic mouse models of GBM and that this access is associated with defects in the BBB rather than transcytosis across the tumor-associated vasculature. We found that perivascular Sox2+/CD44+-tumor cells are largely responsible for internalization of bevacizumab within the niche. In CD133+/Sox2+ cells, propagated in media without addition of growth factors, this internalization occurs through a mechanism consistent with macropinocytosis and that a fraction is localized to a ‘fast’ recycling compartment independent of FcRn and another fraction is localized to the lysosome. The macropinocytosis of bevacizumab and its trafficking to the lysosome promotes survival of the CD133+ cell survival, as does the autophagy induced by the bevacizumab-mediated depletion of VEGF-A.

**Materials and Methods**

**Cells**

Normal brain ECs (isolates 422 and 376) were purchased from Cell Systems; tumor-associated ECs (TECs) were isolated and propagated from primary human GBM tumors (20); CD133+ cells and the matched (paired) CD133-negative (non-stem) tumor cells were isolated from two human GBM xenograft tumors (08-387 and 4121) (21); and MM.1R...
human myeloma cells were purchased from the ATCC. Propagation of the cells and their authentication was as described in the Supplemental Methods.

**Reagents**

Described in the Supplemental Methods.

**Expression of FcγRIIB in myeloma cells**

FcγRIIB cDNA was purchased (EX-ZO435-Lv105, GeneCopoeia) and a lentivirus vector created and used to transduce MM.1R myeloma cells (22).

**Animal Studies**

All studies were performed with the approval of the Animal Use and Care Committee of the Cleveland Clinic, Mayo Clinic or Emory University School of Medicine. The CD133+ orthotopic GBM, the PDX orthotopic GBM, and the syngeneic somatic gene transfer GBM models were generated as described (21,23,24), with details provided in the Supplemental Methods. The CD133+ and PDX models were established and treated with bevacizumab as described in the Supplemental Methods and Figure Legends. The somatic gene transfer model was generated and treated with rat anti-mouse-VEGF-A (25) as described in the Supplemental Methods and Figure Legends.

**Immunofluorescence**

CD133+ GBM cells were plated overnight on chamber slides coated with 20 µg/ml laminin (R&D Systems #3400-00-01) in neural basal media (NBM) without addition of epidermal growth factor (EGF) or basic-fibroblast growth factor (bFGF). Maintenance of the stem-cell phenotype was verified by Sox2 expression (26,27). The following day, a clinically relevant concentration (250 µg/ml) (28) of bevacizumab was added to the media. After incubation (37°C, 5% CO₂) for 5 min, the cells were washed and fixed, or fresh media was added and the cells incubated for the times indicated. To detect internalized bevacizumab, cells were fixed with 4% buffered-paraformaldehyde, blocked, and reacted with Alexa-488-anti-human IgG, then mounted in media containing DAPI nuclear stain (Vector Lab #280772). Double-label immunofluorescent analysis was performed as described previously (20,29). Additional details are found in the Supplemental Methods.

**Cytotoxicity Assay**

This assay was performed according to the manufacturer’s instructions (CytoTox-Fluor™ Cytotoxicity Assay, Promega).

**ELISA Assays**

VEGF-A, VEGF-C and placental growth factor (PGF) were measured using VEGF-A&C (RayBiotech) and PGF (R&D-Systems) ELISA Assay Kits as recommended by the manufacturer.
**Statistical Analysis**

All statistical analyses were performed or overseen by the biostatistician (ASN). The test used is stated in the Figure Legends. A p-value < 0.05 was considered significant.

**Results**

**Bevacizumab gains access to the perivascular space and is internalized predominantly by perivascular Sox2\(^*\)/CD44\(^*\)-tumor cells in orthotopic xenograft and syngeneic mouse models of GBM**

To determine whether bevacizumab can gain access to the perivascular space in GBM, we used a mouse model in which bevacizumab or a control hIgG was administered (i.v., 5 d) to mice with established GBM tumors. Bevacizumab and hIgG were detected in frozen sections of the brain by labeling with an Alexa-488-anti-human-IgG (green) and their location assessed by co-staining with anti-von Willebrand factor (vWF), a marker of ECs, and Alexa-594-conjugated secondary antibody (red) together with nuclear staining using DAPI (blue). Both bevacizumab and the control hIgG were detectable in the perivascular space of the orthotopic GBM tumors (SFig. 1A & B). Very little bevacizumab or hIgG was detected in the perivascular space of uninvolved brain from the mouse model (SFig. 1A & B), consistent with prior studies indicating that minimal amounts of hIgG gain access to the perivascular tissue when the BBB is intact (30).

This analysis further indicated that bevacizumab is internalized by perivascular tumor cells in the GBM xenografts (SFig. 1A & B). Using serial sections of xenograft tumors, we verified that the perivascular cells were human tumor cells by double-labeling with mAb anti-Sox2 and a rabbit antibody to human nuclei (SFig. 1C). The relative distribution of bevacizumab in the Sox2\(^+\) cells versus activated microglia/macrophages was determined using intracerebral GBM xenograft tumors obtained from mice in which the tumor was established and then bevacizumab administered until euthanasia. Sections of the tumors were stained with antibodies to Sox2 and Iba1 (27,31), and the fluorescent intensity of bevacizumab quantified. Although both perivascular Sox2\(^+\) cells and Iba1\(^+\) cells internalized bevacizumab, the bevacizumab-intensity was ~2.5-fold higher in the perivascular Sox2\(^+\) cells than perivascular Iba1\(^+\) cells (Fig. 1A & B). On measuring the distance of Sox2\(^+\) and Iba1\(^+\) cells from the nearest blood vessel, we did not find a difference in proximity (Fig. 1C), consistent with the known localization of both cell types to the perivascular niche (1), although we did find that the mean number of Sox2\(^+\) cells was higher than the mean number of Iba1\(^+\) cells within a 25-µm-radius of the nearest blood vessel (Fig. 1D).

These observations were confirmed using an established immunocompetent mouse model in which GBM tumors were induced by PDGF-B and then treated for two weeks with rat anti-mouse-VEGF-A IgG followed by euthanasia. CD44\(^*\) marks cancer stem-like cells in this model (32) and we found that they also express Sox2 (SFig. 1D). Tumor sections were stained with antibodies to CD44 or Iba1, as well as vWF, and the fluorescent intensity of rat anti-mouse-VEGF-A IgG quantified. We found that both perivascular CD44\(^+\) and Iba1\(^+\) cells within a 25-µm radius of blood vessels internalized anti-mouse-VEGF-A. The rat anti-mouse-VEGF-A-intensity was ~5-fold higher in the CD44\(^+\) perivascular cells as compared...
to that in the Iba1+ perivascular cells (Fig. 1E & F). The distance of CD44+ perivascular cells from the nearest blood vessel was slightly less than that for Iba1+ cells (Fig. 1G).

**Bevacizumab induces autophagy in perivascular tumor cells in the xenograft model of GBM**

We then determined whether there were differences in apoptosis of the perivascular tumor cells in the bevacizumab- and placebo-treated xenograft tumors by double labeling for cleaved caspase-3 and Sox2. We did not find a significant difference in the numbers of apoptotic Sox2+ cells in bevacizumab-treated as compared to placebo-treated tumors (p = 0.50) (Fig. 2A & B). To determine whether bevacizumab induced autophagy, we examined the colocalization of LC3 puncta with LAMP2 (33). We found a significantly higher number and greater area of LC3 puncta colocalized with LAMP2 in the bevacizumab-treated as compared to the placebo-treated tumors (Fig. 2C–E), suggesting that bevacizumab therapy of GBM xenografts induces autophagy in vivo.

**Internalization of bevacizumab by CD133+ cells from GBM into actin-containing membrane ruffles that is blocked by an inhibitor of macropinocytosis**

To confirm that CD133+ cells are able to take up bevacizumab, we analyzed CD133+ cells isolated from xenograft tumors from two different patients with GBM. The CD133+ cells are also Sox2+ (SFig. 1E). The cells were seeded on laminin in NBM without EGF and bFGF to replicate the nutrient-starved condition in GBM tumors. We found that, under these conditions, bevacizumab was internalized rapidly (5 min) by the CD133+ cell isolates from both patients (Fig. 3A).

Double-label immunofluorescence of the CD133+ cells for actin (Alexa-488-phalloidin; green) and bevacizumab (Alexa-647-anti-human IgG; magenta) showed that bevacizumab was internalized into membrane ruffles surrounded by actin (Fig. 3B). This was suggestive of macropinocytosis, which is differentiated from other types of endocytosis by the requirement for remodeling of the actin cytoskeleton with polymerized actin in membrane ruffles. Macropinocytosis is blocked by inhibitors of the Na(+)/H(+) ion exchange pump, such as 5-(N-Ethyl-N-isopropyl)amiloride (EIPA) (16,18,34), and tetramethylrhodamine(TMR)-70-kDa-Dextran is known to be internalized by macropinocytosis (18). The macropinocytic capabilities of the CD133+ cells were confirmed by their rapid internalization of TMR-70-kDa-Dextran (5 min) through a mechanism that was inhibited by EIPA (Fig. 3C & D). The internalization of bevacizumab by the two isolates of CD133+ cells was inhibited significantly by pretreatment with EIPA (Fig. 3E & F). In contrast, the internalization of bevacizumab was not inhibited significantly by EIPA pretreatment of the paired non-stem tumor cells (Fig. 3G and SFig. 2). Taken together, these data suggest that CD133+ cells, but not the paired CD133-negative (non-stem) tumor cells, utilize macropinocytosis to internalize bevacizumab.

**In CD133+ cells from GBM, a fraction of bevacizumab co-localizes with a marker of a recycling compartment and a fraction with a marker of the late endosome/lysosome**

Internalized receptors or proteins can be recycled to the cell surface or targeted for degradation. The routes are differentiated based on their kinetics and the markers expressed...
on the intracellular vesicles. Rab4 marks a ‘fast’ recycling compartment (t_{1/2} ~ 5 min) and also is involved in ‘slower’ recycling through the endosomal recycling complex (t_{1/2} ~15–30 min) (17,35). LAMP1 is a marker of the late endosome/lysosome (17). We therefore examined the colocalization of bevacizumab with Rab4 and LAMP1 (17,35). CD133^+ cells were seeded as described above on laminin and colocalization determined at various time points after treatment with bevacizumab. Rapid, transient colocalization with Rab4 was observed. At 5 min bevacizumab was predominantly (68%) colocalized with Rab4, with this colocalization dissipating at 30 min (20%) (Fig. 4A & B). At 3 h, a large fraction of bevacizumab was colocalized with LAMP1 (~55%) (Fig. 4C & D). Similar results were observed on analysis of CD133^+ cells isolated from a different GBM tumor (SFig. 3A & B). Analysis of hlgG by CD133^+ cells using the same protocol revealed a similar pattern of trafficking (SFig. 3C & D). In sections from three different tumor-bearing mice administered bevacizumab, we found co-localization of bevacizumab with Rab4 or LAMP1 in perivascular tumor cells (Fig. 4E & F), suggesting similar trafficking of bevacizumab in a xenograft mouse model of GBM as found in CD133^+ cells in vitro. Similar trafficking of rat IgG was found in perivascular tumor cells in the established immunocompetent model of GBM treated with rat anti-mouse-VEGF-A (SFig. 3E & F).

FcRn is known to recycle human IgG in ECs (13,14). We confirmed that FcRn expression was detectable in isolates of normal brain ECs (376 and 422) by western blotting using two different FcRn-specific antibodies. However, FcRn expression was not detectable in CD133^+ cell isolates on western blotting using either of these antibodies (Fig. 4G and SFig. 3G & H). FcRn was detectable in the isolates of the paired CD133-negative non-stem tumor cells (Fig. 4G). On stripping of the membrane and reprobing for Sox2, Sox2 expression was detected in the CD133^+ cells whereas a faint band representing Sox2 was detectable in one isolate of the CD133-negative non-stem tumor cells (Fig. 4G). Sections from five xenograft tumors were double-labeled for FcRn and vWf, or FcRn and Sox2, and we found 72% of the FcRn fluorescence (adjusted mean) colocalized with vWf in endothelial cells and 16% of the FcRn fluorescence (adjusted mean) colocalized with Sox2^+ cells (SFig. 4), suggesting that the large majority of Sox2^+ cells do not express FcRn in vivo. As it has been suggested that FcyRIIB can recycle immune complexes in dendritic cells (36), we also examined expression of FcyRIIB on the CD133^+ cells. Myeloma cells (MM.1R) transduced with FcyRIIB were used as a positive control. FcyRIIB was not detected on the CD133^+ cells (SFig. 3G & H).

Bevacizumab binds VEGF-A with high affinity and CD133^+ cells from GBM synthesize and secrete VEGF-A. Potentially, the bevacizumab-VEGF-A complex could be trafficked differently from free bevacizumab. To characterize the trafficking of bevacizumab-VEGF complexes in CD133^+ cells, biotinylated-VEGF-A was incubated with bevacizumab for 1 h and the mixture added to the CD133^+ cells for 5 min, and either fixed or fresh media added for 3 h before fixing. In this experiment, the Mander’s coefficient was calculated as a measure of the percentage of bevacizumab (green) co-localized with VEGF (magenta) that was co-localized with Rab4 or LAMP1 (red) (ImageJ with JACoP-plug-In). At 5 min, 76% of the bevacizumab-VEGF complex was co-localized with Rab4 (SFig. 5A & C), and at 3 h, 47% was co-localized with LAMP1 (SFig. 5B & D). These data suggest that in the GBM
CD133+ cells, the unbound bevacizumab and the bevacizumab-VEGF-A complex are trafficked similarly.

**Effects of bevacizumab on the expression of VEGF-A&C and PGF by CD133+ cells**

Bevacizumab neutralizes VEGF-A and, thus, could induce VEGF-A-depletion in treated cells. VEGF-C also binds VEGFR2 and activates its signaling (37). Bevacizumab can induce expression of PGF (a VEGF family member), which binds and activates VEGFR1 and may indirectly activate VEGFR2 through several mechanisms (38,39). Therefore, we examined the expression of VEGF-A&C and PGF in the CD133+ cells plated as above (in the absence of added growth factors) and treated with bevacizumab. VEGF-A, VEGF-C and PGF were detected in the media of CD133+ cells, and the levels increased from 24–48 h (Fig. 5A–C). With bevacizumab treatment, the levels of VEGF-A were markedly reduced whereas the levels of VEGF-C and PGF were unchanged (Fig. 5A–C). Although there was a reduction in phospho-VEGFR2 in the CD133+ cells on bevacizumab depletion of VEGF-A, phospho-VEGFR2 was still detectable (SFig. 6A & B).

**Macropinocytosis of bevacizumab promotes proliferation of CD133+ cells and bevacizumab depletion of VEGF-A induces a pro-survival autophagy**

To determine whether bevacizumab depletion of VEGF-A induced autophagy in the CD133+ cells, we examined the colocalization of LC3 puncta with the lysosomal marker LAMP2 (33), as well as examining the effect of bevacizumab on cell cytotoxicity/death and viability/proliferation. The concentration of bevacizumab we used had been reported previously to induce autophagy in GBM and cancer stem cell-like GBM cells (40). We found significantly higher autophagy and no change in cell death in bevacizumab-treated CD133+ cells as compared to vehicle at 24 h (Fig. 5D & E). Treatment with hIgG at the same concentration decreased autophagy and had no effect on cell death at 24 h (Fig. 5D & E). Downregulation of VEGF-A with siRNA in the CD133+ cells increased the colocalization of LC3 puncta with LAMP2 as compared to the control siRNA at 48 h (SFig. 6C), suggesting bevacizumab depletion of VEGF-A in the media causes a growth factor-starvation-induced autophagy. To optimally assess viability/proliferation, an MTT assay was performed at 48 h, and indicated that bevacizumab treatment resulted in higher viability/proliferation as compared to the vehicle control (Fig. 5F). These results suggest macropinocytosis of IgG, followed by its lysosomal trafficking and non-specific degradation provided basic building blocks that promoted viability/proliferation. Blocking macropinocytosis of bevacizumab with EIPA treatment at 48 h significantly increased autophagy and cell death (Fig. 5G & H). EIPA treatment also increased autophagy and cell death in vehicle-treated CD133+ cells, but the increase in cell death was greater in the absence of bevacizumab treatment (Fig. 5G).

Treatment with BafilomycinA1, which blocks lysosomal acidification and autophagy (33), caused a significant reduction in co-localization of LC3 puncta with LAMP2 in the bevacizumab-treated CD133+ cells and an increase in cell death (Fig. 5G & H). Taken together, these data suggest that macropinocytosis and lysosomal trafficking of bevacizumab and other proteins promotes CD133+ cell survival and proliferation *in vitro*, and that autophagy induced by bevacizumab depletion of VEGF-A also promotes survival.

_Clin Cancer Res. Author manuscript; available in PMC 2018 November 15._
**Trafficking of bevacizumab in GBM does not involve significant transcytosis across normal brain ECs or ECs isolated from GBM tumors (TECs)**

Transcytosis (reviewed in (41)) across ECs is regulated in normal brain, but potentially could be abnormal in TECs. Using a standard *in vitro* transcytosis assay for normal brain ECs (41), we compared transcytosis of bevacizumab across monolayers of normal brain ECs and TECs. Quantitation of the bevacizumab in the lower chamber by ELISA assay showed that ~30% of bevacizumab was transcytosed across both normal brain ECs and TECs over 2 h (SFig. 7A). There was a 2-fold larger permeability coefficient for 70-kDa-FITC-Dextran in TECs as compared to the normal brain ECs (SFig. 7B). Both normal brain ECs and TECs internalized bevacizumab over 30 min (SFig. 7C & D). Collectively, these data suggest that transcytosis of bevacizumab is not enhanced in TECs, supporting the concept that bevacizumab gains access to the perivascular tumor space in GBM due to alterations in the BBB.

**Discussion**

We demonstrate that bevacizumab gains access to the perivascular tumor niche in established orthotopic mouse models of GBM through the well-described alterations in the BBB, suggesting that vascular normalization by bevacizumab does not occur in 100% of tumor vessels. We found that the CD133+/Sox2+ cells and the paired non-stem tumor cells can internalize bevacizumab but do so through different mechanisms and that, *in vivo*, Sox2+/CD44+ perivascular tumor cells appear to largely be responsible for anti-VEGF-A IgG internalization. We further show that the intracellular trafficking of anti-VEGF-A IgG in GBM tumors affects the survival of CD133+/Sox2+ cells.

Under the conditions used in these experiments, the CD133+ cells internalized bevacizumab and hIgG through the process of macropinocytosis, based on our observation of actin-enriched plasma membrane ruffles surrounding and engulfing bevacizumab into large vesicles and significant inhibition of internalization by EIPA. While macropinocytosis appeared to be the primary mechanism underlying the internalization of bevacizumab in the CD133+ cells, we cannot rule out the possibility of a minor role for another clathrin-independent mechanism. The paired non-stem tumor cells internalized much less bevacizumab and, as the internalization was not affected significantly by treatment with EIPA, macropinocytosis did not appear to contribute to the internalization in these cells.

Analysis of the intracellular trafficking of bevacizumab and hIgG *in vitro* showed colocalization with established markers of endocytic compartments in CD133+ cells, providing clues to the potential fate of the internalized bevacizumab. Under the experimental conditions without added growth factors, bevacizumab was largely co-localized with a marker of a ‘fast’ recycling compartment (Rab4) at 5 min. This would suggest that a considerable amount of the internalized bevacizumab is recycled rapidly to the extracellular environment where it would be available to bind and neutralize VEGF-A. FcRn has been shown to be responsible for the recycling of endogenous IgG in ECs and several other cell types (reviewed in (13)). The time course for bevacizumab and human IgG recycling by the CD133+ cells was faster than has been described for FcRn (14). Moreover, we found that the CD133+/Sox2+ cells do not express FcRn by western blot analysis and that the large

*Clin Cancer Res. Author manuscript; available in PMC 2018 November 15.*
majority of Sox2+ perivascular tumor cells do not express FcRn in vivo. Thus, FcRn was unlikely to play a role in the recycling of bevacizumab and hIgG in the CD133+ cells. Similarly, the inhibitory FcγRIIB has been shown to endocytose and recycle immune complexes back to the cell surface on dendritic cells (36), but we did not detect FcγRIIB on the CD133+ cells by western blotting. The isoelectric point (pl) of humanized IgG mAbs has been shown to affect clearance with a higher pl promoting clearance in a manner that was FcRn independent and presumed to be due to an increased rate of fluid phase endocytosis (reviewed in (42)). Bevacizumab has a higher pl (pl=8.3) (http://www.drugbank.ca) than endogenous IgG (pl=7.2). Although we did not compare the rates of internalization of bevacizumab and hIgG, we did find similar trafficking patterns in the CD133+ cells.

Delivery of the endosome cargo to the late endosome/lysosome is slower than its delivery to the recycling compartment (17). We found that in the CD133+ cells a large amount of bevacizumab colocalized with a marker of the late endosome/lysosome (LAMP1) at 3 h. This is consistent with the report of localization of bevacizumab to the lysosome in retinal ECs at 72 h post-treatment in vitro (43). This localization to the lysosome suggests that the CD133+ cells in the perivascular tumor space also degrade bevacizumab. The percentage of bevacizumab localized to the LAMP1 compartment is probably an underestimate as that pool of bevacizumab is undergoing degradation. In the early endosome, differential sorting of cargo protein to a recycling compartment or the lysosome can be based on specific cargo protein signals (17), including ubiquitination that signals sorting of membrane proteins to the lysosome (44).

The trafficking of the bevacizumab-VEGF-A complex was similar to the trafficking of bevacizumab alone in the CD133+ cells; a fraction co-localized with a marker of the ‘fast’ recycling compartment (Rab4) at 5 min (75%) and a fraction co-localized with a marker of the late endosome/lysosome (LAMP1) (47%) at 3 h. In ECs, the VEGF-VEGFR2 complex is known to be internalized and recycled by different mechanisms, including clathrin-coated pit and endophilin-dependent mechanisms (45,46), but in tumor cells the internalization and trafficking of the VEGF-VEGFR2 complex is not as well-defined.

We show that bevacizumab trafficking directly affects two survival pathways in the CD133+ cells. First, bevacizumab in the perivascular space depletes CD133+ cell-secreted VEGF-A causing a growth factor-deprivation-induced autophagy. This is demonstrated by the significantly higher number and area of LC3-LAMP2 puncta when the CD133+ cells are treated with bevacizumab as compared to vehicle; an increase in numbers of LC3-LAMP2 puncta when VEGF-A is downregulated with siRNA but not when the cells are treated with control siRNA; and a decrease in LC3-LAMP2 puncta on treatment of the cells with hIgG. BafilomycinA1 treatment (inhibits lysosomal acidification) blocked the increase in number and area of LC3-LAMP2 puncta in CD133+ cells treated with bevacizumab. The significant decrease in cell death with bevacizumab treatment at 48 h supports the concept that bevacizumab induces a pro-survival form of autophagy in the CD133+ cells. Autophagy is generally a survival mechanism by which cells that are stressed due to nutrient deprivation, absence of growth factors, or hypoxia metabolize organelles, misfolded proteins and aggregated proteins, thereby generating molecules that allow the cell to survive (33,47). Previously, others have reported an increase in autophagy on bevacizumab treatment of

*Clin Cancer Res.* Author manuscript; available in PMC 2018 November 15.
GBM cells cultured in media with growth factors or under hypoxic conditions (40,48), but the effect of bevacizumab on VEGF-A secreted by tumor cells was not examined. Secondly, our data suggest that the macropinocytosis of bevacizumab followed by its targeting to the lysosome promotes the survival of CD133+ cells due to the increased availability of basic building blocks (amino acids) for the cell. This is supported by the increased viability/proliferation we observed with bevacizumab treatment, and the significant increase in cell death we observed on inhibition of macropinocytosis using the inhibitor EIPA. EIPA treatment also significantly increased autophagy presumably by blocking the macropinocytosis of nutrients and bevacizumab by the cell. The increase in cell death and autophagy taken together point to the possibility that EIPA induces autophagic cell death. The increase in cell death associated with EIPA treatment was significantly lower in bevacizumab-treated CD133+ cells than vehicle-treated CD133+ cells, and this is likely due to the protective growth factor-deprivation-induced autophagy that bevacizumab promotes in the CD133+ cells.

Macropinocytosis is highly regulated and thought to be stimulated by growth factors (16,17). The macropinocytosis of bevacizumab by CD133+ cells occurred in the absence of exogenous growth factors, suggesting that an autocrine or paracrine growth factor pathway may be promoting this process, such as the VEGF/VEGFR2 pathway or another growth factor signaling pathway. VEGF-A has been reported to be a pro-angiogenic growth factor secreted by CD133+ cells from GBM (7). Our data support this concept and further suggest that the CD133+ cells are addicted to VEGF-A. When VEGF-A is depleted by bevacizumab treatment the cells undergo autophagy. Despite depletion of VEGF-A with bevacizumab, phosphorylated-VEGFR2 was still detectable in CD133+ cells although the level of phosphorylation was reduced. This could be due to CD133+ cell secretion of VEGF-C, and/or to a ligand-independent VEGFR2 signaling mechanism. Growth factor receptors also can be macropinocytosed by cells, e.g., the macropinocytosis and lysosomal targeting of the EGF receptor (EGFR) when bound by a combination of mAb anti-EGFR (cetuximab) and anti-human IgG has been reported in large vessel ECs transfected with EGFR (49).

Our studies of the trafficking of anti-VEGF antibody when administered to established xenograft and syngeneic mouse models of GBM indicate the IgG gains access to the perivascular tumor tissue and is internalized predominantly by perivascular Sox2+/CD44+-tumor cells. Furthermore, in these cells, a fraction of bevacizumab is co-localized with Rab4 and a fraction with LAMP1, suggesting similar trafficking of bevacizumab in vivo as we found in CD133+/Sox2+ cells in vitro. Supporting our in vitro data, in bevacizumab-treated xenograft tumors there was increased colocalization of LC3 puncta with LAMP2 in perivascular tumor cells as compared to placebo-treated tumors, suggesting bevacizumab induced autophagy in vivo in the xenograft model. Other investigators have shown that bevacizumab treatment induces autophagy in tumor cells in GBM xenograft models and this was attributed to upregulation of interferon regulatory factor-1 or hypoxia in tumor cells (40,48).

In summary (Fig. 6), our data suggest that (i) CD133+/Sox2+ cells in media without addition of growth factors macropinocytose bevacizumab, and a fraction is trafficked to a ‘fast’ recycling compartment independent of FcRn and a fraction to the lysosome; (ii)
Bevacizumab trafficking promotes CD133+ cell survival through two pathways: the macropinocytosis and lysosomal trafficking of bevacizumab that generates basic building blocks for the cell and growth factor deprivation-induced autophagy; and (iii) In vivo, anti-VEGF-A antibody localizes to the perivascular tumor tissue suggesting it can target tumor-secreted VEGF, is similarly trafficked in perivascular tumor cells and induces a pro-survival autophagy. It should be noted that we are not suggesting bulk effects on the levels of bevacizumab. Rather, we demonstrate a significant effect on the survival of a population of tumor cells in the perivascular microenvironment that are resistant to radiation and chemotherapy and have been suggested to be cancer stem cell-like cells. We have not addressed whether the uptake of bevacizumab could be affecting other clinically relevant processes, such as the expression of GLUT3 (50), the consequences of the survival of the perivascular cancer stem-like cells after bevacizumab treatment, or the mechanisms that trigger their subsequent expansion and potential aggressive invasiveness (2). As bevacizumab also is used to treat renal, colon and lung cancer and as we observed similar trafficking of bevacizumab and hIgG, these studies may have applicability to other cancers in which FcRn is not expressed on cancer stem cell-like cells or tumor cells and to other mAb therapeutics.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

We thank Dr. Judy Drazba (Imaging Core) for assistance, Dr. Fiona Hunter for critically reading the manuscript, and Drs. Qing Yi and Qiang Wang for the gift of MM.1R cells transduced with FcγRIIB.

**Financial Support:** This research was supported by NIH grants R01CA175120 (C.L. Gladson), U01 CA160882 (D. Hambardzumyan), R01CA176830 and Mayo Brain Tumor SPORE P50 CA108961 (J.N. Sarkaria), and Velosano Foundation funding (C.L. Gladson). The Leica-SP5-confocal/multi-photon microscope utilized was purchased with partial funding from NIH SIG-grant 1S10RR026820-01.

**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BBB</td>
<td>blood brain barrier</td>
</tr>
<tr>
<td>bFGF</td>
<td>basic-fibroblast growth factor</td>
</tr>
<tr>
<td>EIPA</td>
<td>5-(N-Ethyl-N-isopropyl)amiloride</td>
</tr>
<tr>
<td>ECs</td>
<td>endothelial cells</td>
</tr>
<tr>
<td>EGF</td>
<td>epidermal growth factor</td>
</tr>
<tr>
<td>EGFR</td>
<td>EGF receptor</td>
</tr>
<tr>
<td>FcRn</td>
<td>embryonic Fc receptor</td>
</tr>
<tr>
<td>GBM</td>
<td>glioblastoma</td>
</tr>
<tr>
<td>hIgG</td>
<td>human IgG</td>
</tr>
</tbody>
</table>
mAb  monoclonal antibody
NBM  neural basal media
PGF  placental growth factor
TECs  tumor-associated ECs
TMR-70-kDa-Dextran  tetramethylrhodamine-70-kDa-Dextran
VEGF  vascular endothelial growth factor
VEGFR  VEGF receptor
vWf  von Willebrand factor

References


**Statement of Translational Relevance**

We found that bevacizumab is internalized by perivascular Sox2\(^+\)/CD44\(^+\) tumor cells *in vivo* in orthotopic xenograft and syngeneic mouse models of glioblastoma. Bevacizumab was internalized by macropinocytosis in CD133\(^+\)/Sox2\(^+\) tumor cells and when trafficked to the lysosome promoted tumor cell survival, as did the autophagy induced by bevacizumab depletion of VEGF-A. As we observed similar trafficking of bevacizumab and human IgG in CD133\(^+\) tumor cells, these findings provide important insight into a new potential mechanism of resistance to bevacizumab or other monoclonal antibody therapies. Bevacizumab also is used to treat renal, colon and lung cancer; thus, these studies may have applicability to other cancers.
Figure 1.
Bevacizumab gains access to the perivascular tumor space and is internalized predominantly by perivascular Sox2+/CD44+ tumor cells in PDX xenograft and syngeneic mouse models of GBM. A–D, PDX GBM tumors (G39 or G59) were injected intracerebrally into the nude mouse (300,000 cells), and treatment with bevacizumab (5 mg/kg, i.p., 2X/week) or placebo initiated on day 13 (G39) or day 28 (G59). Treatment was continued until the development of neurologic signs at day 23 (G39) or day 50–77 (G59), followed by euthanasia, brain harvest, freezing in OCT media, and storage at −80°C. Sections from three mouse tumors from each of the two GBM xenografts treated with bevacizumab were reacted with
Alexa-488-anti-hIgG (green) and anti-Sox2 (2.5 µg/ml) or anti-Iba1 (0.5 µg/ml) antibody (red), and rabbit or mouse anti-vWf (5 µg/ml or 2 µg/ml, respectively) antibody (blue), followed by Alexa-594-conjugated- and Alexa-647-conjugated secondary antibodies and DAPI nuclear stain (A). Area of tumor from mouse administered bevacizumab shown. Arrows denote bevacizumab in Sox2⁺ tumor cells or in Iba1⁺ activated microglia/macrophages (A). Scale bars denote 10-µm (A). Bevacizumab fluorescent intensity in Sox2⁺ or in Iba1⁺ perivascular cells was quantitated as the mean signal intensity/field area and as the mean signal/cell using ImageJ in the six bevacizumab-treated G39 and G59 GBM xenograft tumors (B). The mean distance of bevacizumab-positive Sox2⁺ or Iba1⁺ perivascular cell from the nearest EC was quantitated using ImageJ on the same six xenograft tumors (C). The mean number of Sox2⁺ or Iba1⁺ cells within a 25-µm radius of vWf-positive blood vessels was quantitated on the same six xenograft tumors (D). E-G, The syngeneic somatic gene transfer model of GBM was generated by intracerebral injection of four 6- to 8-week-old Ntv-a/ink4a–arf⁻/⁻ mice with RCAS-PDGF-B-HA. After four weeks, treatment with rat anti-mouse VEGF-A IgG (5 mg/kg, i.p., 2X/week) was initiated and continued for 2 weeks, followed by euthanasia, brain harvest, fixation in 4% paraformaldehyde, immersion in sucrose and freezing (−80°C). Tumor bearing sections (5-µm) were reacted with Alexa-488-anti-rat IgG (green), sheep anti-mouse CD44 (5 µg/ml) or rabbit anti-Iba1 (red), and rabbit or mouse anti-vWf, respectively (as above) (blue), followed by Alexa-594 and Alexa-647-conjugated secondary antibodies, and DAPI nuclear stain (E). Rat anti-mouse-VEGF-A fluorescent intensity in CD44⁺ or in Iba1⁺ perivascular cells was quantitated as the mean signal intensity/cell using ImageJ in the four mice (F). The mean distance of rat anti-mouse-VEGF-A-positive CD44⁺ or Iba1⁺ perivascular cell from the nearest EC was quantitated using ImageJ on the same four tumors (G). Statistical analyses in panels B–D, F&G: linear mixed model.
Figure 2.
Bevacizumab treatment of an orthotopic xenograft model of GBM induces autophagy. A&B, Sections of xenograft GBM tumor from the G39 and G59 PDX tumors treated with bevacizumab or placebo were reacted with rabbit anti-cleaved caspase-3 (0.2 µg/ml) (green) and mAb anti-Sox2 (2.5 µg/ml) (red) antibodies, followed by Alexa-488 and Alexa-594-conjugated secondary antibodies, DAPI nuclear stain and confocal microscopy. Representative photographs of tumor are shown (A). Quantitation of the number of double-labeled cleaved caspase-3 and Sox2 + cells in five representative fields/tumor (B). Data are graphed as Box and Whisker plots. C–E, Sections of xenograft GBM tumor from the G39,
G59 and G44 PDX tumors treated with bevacizumab or placebo were reacted with anti-LC3 (2ug/ml) and anti-LAMP2 (4ug/ml) antibodies, followed by Alexa-488 and Alexa-594-conjugated secondary antibodies, DAPI nuclear stain and confocal microscopy. Representative photographs of tumor are shown (C). Quantitation of the number of LC3-LAMP2-positive puncta/cell in 10 representative fields/tumor (D); the adjusted means are 2.1 versus 0.8 for bevacizumab-treated versus placebo-treated tumors, respectively (p=0.02). Quantitation of the area of LC3-LAMP2-positive puncta/cell in 10 representative fields/tumor (E); the adjusted means are 0.35 versus 0.12 for bevacizumab-treated versus placebo-treated tumors, respectively (p=0.02). Data are graphed as Box and Whisker plots; the green dots represent the adjusted means. In panel D, two data points in the bevacizumab-treated group (10.36 and 14.73) were removed for graphing purposes, but were included in the statistical analysis. In panel E, one data point in the bevacizumab-treated group (3.23) was removed for graphing purposes, but was included in the statistical analysis. Statistical analyses panels B, D and E: linear mixed model.
Figure 3.
Bevacizumab is internalized by CD133+ cells into membrane ruffles in a mechanism consistent with macropinocytosis. A&B, CD133+ cells were plated onto laminin in NBM without bFGF or EGF for 18 h (37°C, 5% CO2), followed by the addition of bevacizumab (250 µg/ml) for 5 min, the cells washed, fixed, reacted with Alexa-647-anti-human IgG (5ug/ml) and Alexa-488-phalloidin (5 units/ml), followed by DAPI nuclear stain, cover slipping, and confocal microscopy. Percent of CD133+ cells from two different tumor isolates (08–387 and 4121) containing bevacizumab-positive vesicles (A). A z-stack of the double-labeling is shown (CD133+ 08–387 cells) (B). White arrows denote phalloidin-
stained cell membrane (green), and red arrows denote bevacizumab-positive vesicle (magenta) surrounded by actin. Scale bar denotes 5-µm. C&D. CD133+ cells (08–387) treated with 50 µM EIPA or vehicle for 30 min (37°C, 5% CO₂), followed by addition of TMR-70-kDa-Dextran (1mg/ml) (red) for 5 min, were washed, reacted with Alexa-488-Phalloidin (green), nuclei stained with DAPI, cover slipped and microscopy performed. In cells treated with vehicle, TMR-70-kDa-Dextran is found in membrane ruffles (white arrows), containing polymerized actin (red arrows) (D). In cells treated with EIPA, reduced amounts of TMR-70-kDa-Dextran are internalized (C&D). The area (µm²) of TMR-70-kDa-Dextran/cell is plotted as the mean±SEM from >100 cells/condition (C). E–G. CD133+ GBM cells (08–387 and 4121) were plated on laminin in NBM as in panels A–D, and paired non-stem tumor cells (CD133-negative 08–387 and 4121) were plated in DMEM with 10% FBS for 18 h. CD133+ cells or the paired CD133-negative tumor cells were treated with vehicle or 50 µM EIPA for 30 min as above, followed by addition of bevacizumab (5 min), and the cells washed, fixed, reacted with Alexa-488-anti-human IgG, followed by DAPI nuclear stain, cover slipping and microscopy. Arrowheads denote bevacizumab-positive vesicles which are reduced in CD133+ cells treated with EIPA (E&F) but are not reduced in CD133-negative tumor cells treated with EIPA (G). The area (µm²) of bevacizumab/cell is plotted as the mean±SEM from >100 cells/condition (F&G). Scale bars denote 10-µm. Statistical analyses: exact two-sided Wilcoxon rank-sum tests.
Figure 4.
Co-localization of a fraction of bevacizumab with Rab4 and a fraction with LAMP1 in CD133+ cells in vitro and in Sox2+ perivascular tumor cells in vivo A–D. CD133+ GBM cells (08–387) were plated for 18 h as in Figure 3, followed by addition of bevacizumab (250 µg/ml) for 5 min, the cells washed and fixed or the media replaced and the cells washed and fixed at the indicated times. The cells were reacted with Alexa-488-anti-human IgG and anti-Rab4 (1:33 dilution of lot#OL196003) or anti-LAMP1 (3.3 ug/ml) antibody, Alexa-594-conjugated secondary antibody, and DAPI nuclear stain, followed by confocal microscopy. Arrows denote co-localization of bevacizumab (green) with Rab4 or LAMP1 (red) (A&C).
The percent bevacizumab co-localized with Rab4 or LAMP1 is plotted as the mean±SEM at the indicated times based on the Mander’s coefficient (B&D). Statistical analyses: Panels B&D, two-sided exact Wilcoxon rank-sum tests. Scale bars denotes 10-µm. E–F, Sections of xenograft GBM tumor from mice that were treated with bevacizumab as in SFig. 1A&B were reacted with Alexa-488-anti-human IgG and anti-Rab4 or anti-LAMP1 antibody, and Alexa-594-conjugated-secondary antibody, followed by DAPI nuclear stain and confocal microscopy. Arrowheads or arrows denote co-localization of bevacizumab (green) with Rab4 (red) (E) or with LAMP1 (red) (F). The box in the far-left image in panels E and F is magnified in the subsequent images. Scale bar denotes 5-µm. G, CD133+ cells (08–387 and 4121) were detergent lysed from cells in suspension culture in NBM without addition of EGF and bFGF; CD133-negative non-stem tumor cells cultured in DMEM with 10% FBS were washed and lysed; and primary brain ECs (isolate #422 or 623) plated on collagen in the recommended media with 10% FBS were washed and detergent lysed. Lysates (50 µg per sample) were electrophoresed on SDS-PAGE, and western blotted with the indicated antibodies.
Figure 5.
Bevacizumab trafficking in CD133+ cells affects two survival pathways. CD133+ cells were plated as in Figure 3 in NBM without addition of EGF and bFGF, treated with bevacizumab or hIgG for 24 or 48 h (1 mg/ml), and the media removed for ELISA assay (A–C), or the cells washed, fixed and reacted with anti-LC3 antibody (2 µg/ml) (green) and anti-LAMP2 antibody (4 µg/ml) (red), followed by Alexa-488 and Alexa-594-conjugated secondary antibodies, DAPI nuclear stain and confocal microscopy (D, G&H), or the cells subjected to a cytotoxicity/death assay (E&G) or an MTT assay (F). A–C, Levels of VEGF-A or VEGF-C or PGF protein in the media of CD133+ cells treated with bevacizumab or vehicle are
graphed as the mean±SEM at the time points shown. The levels of VEGF-A with bevacizumab treatment at 24 and 48 h were 9.18±0.32 pg/ml and 8.04±0.34 pg/ml (mean ±SEM), respectively. **D**, Colocalization of LC3-LAMP2 puncta/cell in CD133+ cells treated with bevacizumab, hIgG or vehicle for 24 h. Quantitation of the area of colocalization (ImageJ) from ten fields/condition is graphed as the mean±SEM. **E**, Quantitation of cell cytotoxicity/death (relative to vehicle) after bevacizumab, hIgG or vehicle treatment for 24 h, and graphed as the mean±SEM. **F**, Quantitation of viability/proliferation in CD133+ cells treated with bevacizumab or vehicle for 48 h. **G**&**H**, Colocalization (ImageJ) of LC3 puncta with LAMP2 (10 fields/condition) or quantitation of cell cytotoxicity/death (relative to vehicle) is shown in CD133+ cells treated with bevacizumab or vehicle for 48 h, with or without inhibitors, and is graphed as the mean+SEM (G). Representative images of the colocalization of the LC3-LAMP2 puncta in the same six conditions is shown (H). Arrows denote co-localization (yellow) (H). Statistical analyses: Panels A–C, and F, two-sided exact Wilcoxon rank-sum tests; D and E, the Steel Method; and G, Wilcoxon rank-sum tests. *Denotes p value < 0.05; **denotes p value < 0.01; ***denotes p value < 0.001; and ****denotes p value <0.0001. n.s., denotes not significant.
Figure 6.
Schematic depicting the effect of bevacizumab trafficking on two survival pathways in CD133+ cells from GBM. Bevacizumab gains access to the perivascular tumor tissue by leakage across an altered BBB, followed by macropinocytosis by CD133+ cells and trafficking to a Rab4 recycling compartment (not shown) or a LAMP1 lysosomal compartment, as well as bevacizumab neutralization of VEGF-A in the perivascular space inducing autophagy. Macropinocytosis of bevacizumab results in partial trafficking to the lysosome where non-specific degradation occurs, and this generates amino acids (basic building blocks) for the cell that promotes survival/proliferation. The depletion of VEGF in the extracellular environment by bevacizumab results in growth factor starvation-induced autophagy that also promotes survival.